Biopharma firm IN8bio's Q2 net loss narrows as expenses decline
INAB•Outlook
The company expects to report initial preclinical animal data for INB-619 in H2 2026.
IN8bio also anticipates providing updates on FDA discussions for the DeltEx DRI GBM program.
The company plans to provide a clinical update on the INB-100 program in late 2026.
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
Wall Street's median 12-month price target for IN8bio, Inc. is $5.50, about 456.2% above its August 5 closing price of $0.99.
Clinical data update
The company reported updated clinical and peer-reviewed data showing improved survival and progression-free survival for glioblastoma patients treated with DeltEx DRI.
- Safety profile - IN8bio said DeltEx DRI showed favorable safety with no dose-limiting toxicities, CRS or ICANS in newly diagnosed GBM patients.
- Immune remodeling - The company reported translational analyses showing DeltEx DRI preserved immune function and remodeled the tumor microenvironment in GBM.
Q2 results and cash position
Biopharma firm IN8bio's Q2 net loss narrowed year over year, with flat R&D and lower G&A expenses.
